Skip to main content

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Acciones de la SHBG y de los receptores de estrógenos en el desarrollo y la progresión a la hormono-resistencia del cáncer de próstata.

IP: Francina Munell Casadesus
Collaborators: Joan Morote Robles
Funding agency: Instituto de Salud Carlos III
Funding: 108215
Reference: PI020772
Duration: 06/11/2002 - 06/11/2005

Investigación y desarrollo de productos y tecnologías de diagnóstico-pronóstico y aplicaciones terapéuticas en la enfermedad neoplásica.

IP: Jaume Reventós Puigjaner
Collaborators: Francina Munell Casadesus, Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Oncnosis Pharma, AIE
Funding: 249550
Reference: CENIT/01/2006
Duration: 19/01/2006 - 31/12/2009

RTICC - Red Temática de Investigación cooperativa de cáncer

IP: Jaume Reventós Puigjaner
Collaborators: Joan Morote Robles, Ma Teresa Quiles Pérez, Francina Munell Casadesus, Eva Colas Ortega, Enric Trilla Herrera, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Tomàs Pinós Figueras, Carles Xavier Raventós Busquets, Maria Antonia Arbos Via, Jacques Planas Morin, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 350549.54
Reference: RD06/0020/0058
Duration: 02/01/2007 - 31/12/2013

Mecanismos moleculares responsables del desarrollo de resistencia a los andrógenos en el cáncer de próstata. Identificación de marcadores predictivos de progresión y de respuesta al tratamiento

IP: Francina Munell Casadesus
Collaborators: Joan Morote Robles
Funding agency: Instituto de Salud Carlos III
Funding: 90440
Reference: PI052684
Duration: 01/01/2006 - 31/05/2009

Related news

The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Related professionals

Francesc Zarzuela Serrat

Francesc Zarzuela Serrat

Research assistant
Infectious Diseases
Read more
Pablo De Luna Martínez

Pablo De Luna Martínez

Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Lluis Armadans Gil

Lluis Armadans Gil

Senior researcher
Epidemiology and Public Health
Read more
Nils jimmy Hidalgo Rivera

Nils jimmy Hidalgo Rivera

Predoctoral researcher
General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.